Acylation stimulating protein stimulates insulin secretion.
Acylation stimulating protein (ASP) is a hormone produced by adipocytes and is of importance for the storage of energy as fat. We examined whether ASP might also have effects on islet function. In clonal INS-1 cells, ASP dose-dependently augmented glucose-stimulated insulin secretion. The lowest effective dose of ASP at 10 mmol/l glucose was 5 micro mol/l. The effect was glucose-dependent because ASP did not increase insulin secretion at 1 mmol/l glucose but had clear effect at 10 and 20 mmol/l glucose. Similarly, ASP augmented glyceraldehyde-induced insulin secretion but the hormone did not enhance insulin secretion in response to depolarization by 20 mmol/l of KCl. ASP-induced insulin secretion was completely abolished by competitive inhibition of glucose phosphorylation by glucokinase with 5-thio-glucose and was partially inhibited by the calcium channel blocker, nifedipine, and by the protein kinase C inhibitor, GF109203. Furthermore, thapsigargin, an inhibitor of Ca(2+)-ATPase in the endoplasmic reticulum, did not affect ASP-induced insulin secretion. ASP (>5 micro mol/l) also augmented glucose-stimulated insulin secretion from islets isolated from C57BL/6J mice, and intravenous administration of ASP (50 nmol/kg) augmented the acute (1 and 5 min) insulin response to intravenous glucose (1 g/kg) in C57BL/6J mice. This was accompanied by an increased rate of glucose disposal. Minimal model analyses of data derived from the intravenous glucose tolerance test revealed that whereas ASP augmented insulin secretion, the hormone did not affect insulin sensitivity (S(I)) or glucose effectiveness (S(G)). We conclude that ASP augments glucose-stimulated insulin secretion through a direct action on the islet beta cells. The effect is dependent on glucose phosphorylation, calcium uptake and protein kinase C. Stimulation of insulin secretion by ASP in vivo results in augmented glucose disposal.
Ahrén
B
B
Department of Medicine, Lund University, Lund, Sweden. Bo.Ahren@med.lu.se
Havel
P J
PJ
Pacini
G
G
Cianflone
K
K
D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D001798:Blood Proteins / Q000494:pharmacology*; D002121:Calcium Channel Blockers / Q000378:metabolism; D002478:Cells, Cultured; D015926:Complement C3a / Q000031:analogs & derivatives*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D005941:Glucokinase / Q000378:metabolism; D005947:Glucose / Q000378:metabolism; D007211:Indoles / Q000494:pharmacology; D007328:Insulin / Q000097:blood / Q000378:metabolism*; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects / Q000378:metabolism; D008301:Maleimides / Q000494:pharmacology; D051379:Mice; D008810:Mice, Inbred C57BL; D009543:Nifedipine / Q000378:metabolism; D010766:Phosphorylation; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D011863:Radioimmunoassay; D019284:Thapsigargin / Q000494:pharmacology
D001786:Blood Glucose; D001798:Blood Proteins; D002121:Calcium Channel Blockers; D004791:Enzyme Inhibitors; D007211:Indoles; D007328:Insulin; D008301:Maleimides; C044541:complement C3a, des-Arg-(77)-; D019284:Thapsigargin; D015926:Complement C3a; D005941:Glucokinase; D011493:Protein Kinase C; D009543:Nifedipine; D005947:Glucose; C070515:bisindolylmaleimide I